Overall, the results of this study indicate that EVs-delivered PFKFB3 small molecule inhibitor quercetin can not only inhibit the inflammatory response in AP but also potentially improve glucose metabolism disorders by regulating glycolysis-related pathways and inhibiting oxidative stress. Here, PFKFB3 is linked to glucose metabolic process.